Pharmaceutical Drug Metformin and MCL1 Inhibitor S63845 Exhibit Anticancer Activity in Myeloid Leukemia Cells via Redox Remodeling

Pharmaceutical Drug Metformin and MCL1 Inhibitor S63845 Exhibit Anticancer Activity in Myeloid Leukemia Cells via Redox Remodeling

Metabolic landscape and sensitivity to apoptosis induction play a crucial role in acute myeloid leukemia (AML) resistance. Therefore, we investigated the effect of metformin, a medication that also acts as an inhibitor of oxidative phosphorylation (OXPHOS), and MCL-1 inhibitor S63845 in AML cell lin...

Full description

Bibliographic Details
Main Authors: Giedrė Valiulienė, Aida Vitkevičienė, Giedrė Skliutė, Veronika Borutinskaitė, Rūta Navakauskienė
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Molecules
Subjects:
acute myeloid leukemia (AML)
metformin
MCL-1 inhibitor S63845
reactive oxygen species (ROS)
Online Access:https://www.mdpi.com/1420-3049/26/8/2303

Similar Items

Similar Items